Immune response to second vaccination series of hepatitis B virus among booster dose non-responders.

Autor: Salama II; Community Medicine, National Research Center, Cairo, Egypt. Electronic address: salamaiman@yahoo.com., Sami SM; Pediatrics, National Research Center, Cairo, Egypt., Salama SI; Community Medicine, National Research Center, Cairo, Egypt., Rabah TM; Community Medicine, National Research Center, Cairo, Egypt., El Etreby LA; Community Medicine, National Research Center, Cairo, Egypt., Abdel Hamid AT; Community Medicine, National Research Center, Cairo, Egypt., Elmosalami D; Community Medicine, National Research Center, Cairo, Egypt., El Hariri H; Community Medicine, National Research Center, Cairo, Egypt., Said ZN; Microbiology & Immunology, Faculty of Medicine (for Girls), Al Azhar University, Cairo, Egypt.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2016 Apr 07; Vol. 34 (16), pp. 1904-8. Date of Electronic Publication: 2016 Feb 28.
DOI: 10.1016/j.vaccine.2016.02.050
Abstrakt: Objective: To evaluate the response to second vaccination series among post-booster sero-negative children who had previously received compulsory HBV vaccination.
Subjects and Methods: After given a booster dose to 1070 children, 103 of them failed to generate anamnestic response (anti-HBs <10 IU/L). Only 91/103 children received additional two doses of recombinant HBV vaccine (i.e. 2(nd) vaccination series) after 1 and 6 months post-booster. Blood sample was withdrawn aseptically one month later for quantitative assessment of anti-HBs to detect development of protective immune response (≥10 IU/L). Immunological vaccination failure was assigned to children who did not develop protective immune response after 2(nd) vaccination series.
Results: Protective immune response was detected among 84/91 children (92.3%). While 7/91 (7.7%) whose age were ≥10 years did not respond and had post-booster undetectable anti-HBs. About 80% of children with post-booster detectable anti-HBs showed significant protective immune response (anti-HBs ≥100 IU/L) and higher GMT (299.1 ± 3.6 IU/L) compared to those with undetectable 60% and 106.2 ± 12.9 IU/L respectively (P<0.05). No significant difference was detected as regards gender or residence, P>0.05. All children with history of rheumatic fever (7 children) or diabetes mellitus (1 child) developed immune response after 2(nd) vaccination series.
Conclusion: A booster dose of HB vaccine may be unable to induce sufficient immunological response in children who had undetectable anti-HBs titers. Revaccination for non-responders is an important procedure to increase HBV protection rate.
(Copyright © 2016 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: